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Introduction
The varicella-zoster virus is transmitted by the airborne route. It is very contagious and 
found world-wide. It is a member of the family of alphaherpesvirus and typically causes 
a vesicular rash on the central areas such as the head, neck and trunk with fever [1]. 
Even with chickenpox, the mild form of primary infection to healthy children may 
cause complications like pneumonia, hepatitis, and even encephalitis. Complication 
risk is likely to be increased in older patients, immune-compromised hosts, and preg-
nant women. It is supposed that the varicella vaccines might protect 85% of chicken-
pox infection and 97% of severe secondary sequelae [2]. For these reasons, several 
countries adopted the varicella vaccine as a mandatory immunization program over 
time; 1986 in Japan, 1995 in the US, and 2005 in Korea [3,4]. In Korea, varicella vaccine 
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Purpose: There are different principles regarding varicella vaccination depending on social 
requirements. This study was performed to report a case of breakthrough chickenpox outbreak 
among a group of people in the healthcare center and also evaluate the seroprevalence of 
patients who have been managed with chronic neurological diseases in this center. 
Materials and Methods: We included patients diagnosed with varicella in April 2009 as an 
index cases and investigated the past history for chickenpox and the varicella-specific IgG. 
Sixty-two patients (children) and 156 healthcare workers who may have had possible contact 
with the index cases were also investigated for. 
Results: We investigated the seroprevalence of 62 patients not affected by the outbreak. The 
varicella vaccination rate in children was 90.3%. Sixty-one point three percent of all patients 
were seropositive and 63.6% of these patients were aged between 12 and 23 months and 87.5% 
were aged between 24 and 35 months. Seropositive rate was decreased for patients aged 
between 36 and 59 months while the seropositive prevalence has increased for patients over 
5 years old. Over 90% of the adults investigated were seropositive. IgG seronegative despite 
vaccination was 32.1% (18 persons).
Conclusion: Breakthrough varicella outbreak can have huge impact in healthcare centers 
with affiliated group housing. We need to investigate vaccination status and immunogenicity 
according to ages and reflect appropriately on vaccination policy taking into consideration of 
social and medical requirements in the local area.
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is mandatory with the current protocol (established 2005) 
suggesting one dose between 12 and 15 months of age. If a 
child has no vaccination confirmed or no history of chicken-
pox before 13 years of age, one-dose of vaccine is recommen-
ded but if the child is over 13 years old without vaccine or chick-
enpox history, he or she is recommended for a two-dose sche-
dule 4 to 8 weeks apart [5]. However, the unwanted phenom-
enon called “breakthrough varicella” or “mild varicella-like 
syndrome” emerged after the introduction of the varicella 
vaccine. It is defined as an infection after exposure to a wild-
type virus strain in the previously vaccinated. Breakthrough 
varicella is known to have less than 3% incidence in vaccinat-
ed children after each year following vaccination. Even 
though most cases of breakthrough varicella are mild, it can 
pose a serious problem because of transmission risk [6-8]. In 
this article, we report a case of breakthrough outbreak of 
chickenpox among a group of people in a healthcare center 
and evaluate the seroprevalence of patients and health care 
workers who might have come in to contact with the index 
case.
Materials and Methods
We selected an initial patient with varicella diagnosed in April 
2009 as an index case and investigated the past history for 
chickenpox and varicella vaccination. Serum samples were 
collected to look for varicella specific-IgM and IgG in 62 pa-
tients and 156 healthcare workers who were thought to have 
had a contact with the initialpatient. Enzyme immunoassay-
for the qualitative detection and quantitative determination 
of specific-IgG antibodies to varicella-zoster virus was per-
formed for each sample and we used Enzygnost anti-VZV 
IgM and IgG from Siemens (Marburg, Germany). The tests 
were based on VZV glycoproteins as antigens. In the result, 
greater than 1:40 was considered as positive for anti-IgM which 
implied acute infected or newly reactivated status and detec-
tionover 50 IU/L was considered positive for anti-IgG which 
showed immunization had been successful. 
Results
The Index case was a patient’s mother. She complained of an 
itching rash on her son’s second day in hospital. Her son was 
hospitalized for rehabilitation at the rehabilitation center, which 
was the communal center of concern. Right after nothing oc-
currence of chickenpox, they were quarantined with respira-
tory isolation. Since that, sixteen cases of outbreak were re-
ported. Two adults including one healthcare worker and four-
teen children were reported as having symptoms of varicella. 
All chickenpox cases had occurred within sixteen days after 
the index casewas recognized. Twelve out of fourteen chil-
dren cases in children had received chickenpox vaccination 
or had a history of previous chickenpox exposure. Two chil-
dren were confirmed as seropositive before they were diag-
nosed with chickenpox. Considering incubation period, the 
end of the outbreak was defined as when no more caseswere 
reported within three weeks from the last known case. The 
time-interval graph of cases after the index cases shown in 
Fig. 1.
 One hundred thirty young patients hospitalized at the same 
ward were identified and placed under cohort follow-up. Six-
ty two among them were analyzed for their seroprevalence. 
Among these 62 young patients, the total vaccination rate 
was 90.3%, IgG seropositivity was 61.3%, 63.6% of these pa-
tients were aged between 12 and 23 months and 18 persons 
were seronegative even though vaccination was performed 
(32.1%)(Table 1). In addition, we checked 156 health care 
workers at exposure risk. These patients self-reported a 70% 
immunization rate from vaccination or past infection and on 
investigation showed a positive seroprevalence rate of 96.2%.
The seropositive rate was high until 12 months of age, then de-
creased by 5 years of age and again increased after that. The 
prevalence of seropositivity over five years old increased to 
over 90% in adults (Fig. 2).
Fig. 1. Varicella cases by dates after development of symptoms ac-
cording to patients.
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Discussion
Breakthrough varicella has become an emerging issue after 
the implementation of vaccine programsin modern times. Its 
symptoms include a maculopapular rash rather than the ve-
sicular appearance which is found in typical varicella infec-
tion, fewer lesions (usually less than 50 lesions) compared to 
over 300 lesions in typical varicella and no fever [3,6,7]. Even 
though it manifests mild symptoms in healthy individuals, it 
may cause an outbreak in groups located in at-risk areas like 
health care centers or clustered facilities. Breakthrough vari-
cella phenomenon can be explained through two ways; the 
first is the failure of the primary vaccine, which suggests the 
failure to produce a protective immune response to the vac-
cine. In a recent study for the etiology of breakthrough vari-
cella, 113 children seroconverted out of 148 vaccines and 24% 
among them had no VZV antibodies detected after the one-
shot vaccine [9]. Marin et al. [10] suggested that the lower se-
roconversion may have been caused by an absence of circulat-
ing wild type viruses which should have boosted host immuni-
ty in early life. In addition, there are other factors related to pri-
mary vaccine failure such as very young age on vaccination, 
the use of steroids, or immune-compromised states [11,12].
 The second explanation of breakthrough varicella is the 
waning of immunity over time [13-15]. The level of protective 
efficacy in other studies has fallen from 97% to 84% at eight 
years after primary varicella immunization [16,17]. The Vari-
cella Active Surveillance Project in California in 1995 to 2004 
studied varicella surveillance cases concerning varicella vac-
cine status at least 42 days after immunization. One thousand 
eighty cases (9.5%) of breakthrough varicella were reported 
out of 11,356 varicella cases and among children ages between 
8 and 12 years who had been vaccinated, children over 5 years 
after vaccination were more likely to have serious disease 
than children who were vaccinated less than 5 years previ-
ously. The annual rate of breakthrough varicella increased 
with the times after vaccination. Varicella infection had more 
cases in breakthrough infection than wild-type infection. How-
ever it did not mean there was increasing vaccine failure or 
breakthrough infection. Overall cases of varicella had decreas-
ed after vaccine program by about 85% in that period [18].
 We reported that breakthrough varicella had occurred in 
most patients who had neurologic deficits and were receiving 
rehabilitative therapy. Depending on age, children had dif-
ferent vaccination histories but in most patients over one year 
of age, seroprevalence for varicella was highly controlled but 
decreasing antibody titers was seen. However, seroprevalence 
for varicella in adults has increased with ages. It is thought be-
cause they might have had asymptomatic contacts with wild-
type varicella.
 Even though breakthrough varicella has a milder manifes-
tation of symptoms, it is still contagious and has a chance to 
create a more serious outbreak in high risk groups. Because 
of primary vaccine failure and waning of immunity, it needs 
to find another way to booster immunity against varicella. 
Additional dose of varicella vaccine can be one option. It is 
known to have an effect of stopping the spread and reducing 
the severity of symptoms [19] but as a national mandatory 
vaccination, the overall cost effectiveness should be consid-
ered. In our study, 15,000,000 KRW (about $130,000 US dol-
lars) were used to perform serological studies and to control 
patients for management. To evaluate the efficacy of the vac-
cine, it needs to consider the management cost as well as the 
direct vaccine cost in situations of exposure. Even though 
Table 1. The characteristics of varicella patients by ages, vaccination 
rate, and seroconversion
Age (mo) Total Male Female Vaccination rate (%)
Seropositive 
rate (%)
0-11   2   0   2     0   0 
12-23 11 10   1   91 64 
24-35   8   3   5 100 88 
36-47 10   4   6 100 50 
48-59   3   2   1   67 33 
60-71   5   2   3   80 60 
≥72 23 10 13   96 65 
Fig. 2. The curve of varicella seroprevalence rate by ages.
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varicella is known to show mild physical symptoms, it can 
still cause significant social and economic burdens. 
 The limitation in our study is following: The number of 
study was too small and study was performed in a specialized 
group so the result of the study could not be easily general-
ized to other groups or population. Also, from an immuno-
logical point of view, there were some cases who suffered 
from varicella infection despite having IgG against varicella. 
It might be explained that they had low titers of IgG against 
varicella or weaker protective effect on varicella infection 
even though they had IgG. Therefore, it needs to find a better 
way to represent for protective immunity against varicella. In 
addition, to increase the protective immunity, the second dose 
of varicella vaccine is adopted in several countries including 
the US but the effectiveness of the second dose of varicella vac-
cine is still short of evidence and needs to be studi ed more.
 In conclusion, to achieve more effective control of varicella 
infection and to maintain protective immunity, further resear-
ches are required with standardized methods to evaluate in-
fection control and more systemic data must be collected 
with multi-centered studies to bolster credibility. Also more 
studies about the effectiveness of an additional varicella vac-
cination are needed in the near future. 
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